The Delhi High Court ruled Dr. Reddy's can export semaglutide, finding Novo Nordisk's patent unenforceable. Dr. Reddy's plans to launch generic Wegovy at 60% discount pending approval.
The FDA announced new enforcement priorities on February 6, 2026, to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs being mass-marketed. The action follows an August 2025 citizens' petition arguing that large-scale compounded semaglutide production poses public health risks including lack of immunogenicity assessments and misleading marketing practices.
Global oncology drug spending is projected to reach $467 billion by 2030, driven by novel modalities like ADCs and bispecifics, but growth will slow due to patent expirations for key drugs like Keytruda and Lynparza. R&D is shifting, with novel modalities accounting for 33% of clinical trials in 2025. The industry is also seeing broader innovation and investment, with new blockbuster contenders emerging across multiple therapeutic areas.
Delaware's state employee health plan may raise GLP-1 copays from $32 to $120 per month or eliminate weight-loss drug coverage entirely, as costs are projected to reach $211 million by 2029. A decision is expected February 23, 2027.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Ten-year follow-up of the phase 3 ESPATUE trial found similar overall and progression-free survival with chemoradiotherapy boost or surgery in resectable advanced NSCLC after induction therapy.
Pharmaceutical M&A is shifting toward late-stage clinical assets with proven human data, particularly in GLP-1 obesity drugs, oncology, and central nervous system disorders. Companies like Viking Therapeutics, Structure Therapeutics, and Revolution Medicines represent compelling acquisition targets with advanced clinical programs. This trend reflects industry prioritization of de-risked assets that can accelerate commercialization pathways.
The FDA has approved Eli Lilly's GLP-1 weight loss pill Foundayo, which will compete with Novo Nordisk's Wegovy pill. Foundayo will be available through LillyDirect and pharmacies, with prices ranging from $25 with insurance to $149-$349 for cash payers. The approval sets up a new battle in the oral GLP-1 market between the two pharmaceutical giants.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07616752 |
The Impact of Salmon Protein Hydrolysate (SPH / ProGo®) Supplementation on Hematologic and Metabolic Health |
COMPLETED | NA |
| NCT07608016 |
A Study to Evaluate a Supplement Combination in Supporting Weight Loss, Metabolic Health, and Quality of Life |
COMPLETED | NA |
| NCT07601061 |
Simplifying Diet Tracking in a Digital Weight Loss Intervention |
NOT_YET_RECRUITING | NA |
| NCT07588984 |
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study |
NOT_YET_RECRUITING | |
| NCT07577765 |
Testing a Tailored Approach to Long-Term Weight Loss Success |
RECRUITING | NA |
| NCT07569172 |
Improved Child Nutrition and Development Through Social Transfers |
NOT_YET_RECRUITING | NA |
| NCT07567937 |
Effects of Exercise and Short Term Rapid Weight Loss on Whole Blood Cells and Lymphocyte Subsets in Highly Trained National Level Wrestlers |
COMPLETED | NA |
| NCT07540754 |
A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function |
RECRUITING | PHASE1 |
| NCT07535892 |
Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation |
NOT_YET_RECRUITING | NA |
| NCT07487090 |
Fasted vs. Fed State Exercise |
RECRUITING | PHASE2 |
